
To assess the contribution of pharmacological tolerance to increasing doses of zzso 29 cancer patients requiring oral zzso to treat pain were studied by two teams working zzso The first team assessed physical zzso pain intensity and pain zzso The second team assessed depressive disorders zzso III zzso emotional and zzso depressive patterns zzso zzso zzso zzso zzso zzso All patients were seen at the initiation of zzso therapy and followed to the first zzso dose zzso zzso were carried out in zzso clinics except staging investigations which were undertaken at the beginning and at the end of the zzso Our results showed that zzso in 24 of the 25 patients for whom zzso doses were increased, progressive disease was recorded; zzso in 4 patients, zzso doses were not increased and in these patients their disease was stable or in zzso and zzso changes in depressed mood were not correlated with pain zzso These data strongly suggest that, instead of pharmacological zzso the main factor resulting in increasing oral zzso requirement in cancer pain management is pain increase due to disease zzso 

